Encompass Health (NYSE:EHC – Get Rating) posted its quarterly earnings results on Thursday. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.70 by $0.18, Briefing.com reports. Encompass Health had a net margin of 5.54% and a return on equity of 16.15%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.14 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. The business’s revenue for the quarter was down 13.0% on a year-over-year basis. Encompass Health updated its FY23 guidance to $2.94-3.23 EPS and its FY 2023 guidance to $2.94-$3.23 EPS.
Encompass Health Price Performance
EHC stock traded up $0.47 during trading on Friday, reaching $63.91. The company’s stock had a trading volume of 820,123 shares, compared to its average volume of 879,881. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.50. The company’s fifty day moving average is $57.70 and its 200-day moving average is $57.37. The company has a market capitalization of $6.37 billion, a P/E ratio of 23.50, a price-to-earnings-growth ratio of 1.49 and a beta of 1.05. Encompass Health has a 1 year low of $44.33 and a 1 year high of $69.77.
Encompass Health Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, April 17th. Investors of record on Monday, April 3rd were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date was Friday, March 31st. Encompass Health’s dividend payout ratio (DPR) is 22.22%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Mizuho increased their price target on shares of Encompass Health from $65.00 to $69.00 and gave the company a “buy” rating in a report on Thursday, February 9th. Truist Financial increased their price objective on shares of Encompass Health from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, February 9th. Barclays increased their price objective on shares of Encompass Health from $57.00 to $61.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 4th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Encompass Health from $62.00 to $70.00 in a research report on Thursday, February 9th. Finally, Stephens restated an “overweight” rating and set a $70.00 price objective on shares of Encompass Health in a research report on Wednesday, February 8th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $69.82.
Insider Activity
In other news, CFO Douglas E. Coltharp sold 17,895 shares of the company’s stock in a transaction dated Friday, February 10th. The stock was sold at an average price of $60.78, for a total value of $1,087,658.10. Following the completion of the transaction, the chief financial officer now owns 53,097 shares of the company’s stock, valued at $3,227,235.66. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.70% of the company’s stock.
Hedge Funds Weigh In On Encompass Health
A number of hedge funds have recently made changes to their positions in EHC. Lazard Asset Management LLC raised its holdings in shares of Encompass Health by 14.3% in the fourth quarter. Lazard Asset Management LLC now owns 1,290 shares of the company’s stock worth $77,000 after buying an additional 161 shares during the period. Bank of Montreal Can increased its holdings in Encompass Health by 1.5% during the 1st quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock worth $806,000 after purchasing an additional 173 shares during the period. Creative Planning increased its holdings in Encompass Health by 3.5% during the 2nd quarter. Creative Planning now owns 6,074 shares of the company’s stock worth $340,000 after purchasing an additional 204 shares during the period. Neuberger Berman Group LLC increased its holdings in Encompass Health by 2.2% during the 1st quarter. Neuberger Berman Group LLC now owns 14,167 shares of the company’s stock worth $1,007,000 after purchasing an additional 306 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its holdings in Encompass Health by 20.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,025 shares of the company’s stock worth $121,000 after purchasing an additional 344 shares during the period. Institutional investors own 96.14% of the company’s stock.
Encompass Health Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
